A Study of Lanadelumab in Teenagers and Adults With Hereditary Angioedema (HAE)
This study is for teenagers and adults in the UK who have a rare condition called Hereditary Angioedema (HAE) where they get sudden swelling attacks. It’s looking at how a medicine called lanadelumab affects these attacks. Researchers want to compare how many attacks people had in the year before they started lanadelumab with how many they have for up to two years after starting it. This will help doctors understand how well lanadelumab helps to reduce HAE attacks, including those that need immediate treatment. Information for the study will come from participants' medical records, diaries, and questionnaires, and they'll be contacted every three months by phone.
A colpo d'occhio
Di cosa tratta questo studio?
This research study is about a medicine called lanadelumab, which is used to treat a condition known as Hereditary Angioedema, or HAE. HAE is a rare genetic condition that causes sudden, painful swelling attacks in various parts of the body, like the hands, feet, face, and airways. These attacks can be very disruptive and sometimes dangerous.
The main goal of this study is to understand how well lanadelumab helps people manage their HAE. Specifically, the researchers want to compare the number of HAE attacks people have in the 12 months before they start taking lanadelumab with the number of attacks they have for up to two years after they begin treatment. They're also interested in seeing if the number of attacks that need urgent treatment changes.
This study is being carried out in the UK and involves people who are already receiving lanadelumab as part of their regular care from their hospital doctors, or who are about to start it. By collecting information directly from participants, their medical records, and their doctors, the study hopes to provide clear evidence on the real-world benefits of lanadelumab for HAE patients.
Punti chiave
- This study looks at how a current HAE medicine, lanadelumab, works in real life.
- It aims to understand if lanadelumab reduces HAE attacks over time.
- Data will be collected from existing medical records, diaries, and phone calls.
- You must be 12 years or older and already on (or starting soon) lanadelumab.
- Participation involves sharing information, not trying new treatments.
Chi può essere idoneo?
To join this study, you need to have a confirmed diagnosis of Hereditary Angioedema (HAE) type I or II, which means it's been properly identified through lab tests. You also need to be 12 years old or older when you start taking lanadelumab, and you must either be already taking lanadelumab or be scheduled to start it within the next four weeks.
Another important point is that your medical records must show at least 12 continuous months of information about your HAE before you started taking lanadelumab. This allows the researchers to compare your HAE attacks before and after starting the medicine.
You cannot be included in this study if you have ever received lanadelumab as part of another research study or clinical trial in the past.
Questo studio potrebbe fare al caso tuo?
Rispondi a queste domande rapide per vedere se potresti essere idoneo. Questo è solo una guida — il team di ricerca prende la decisione finale.
- Do I have a confirmed diagnosis of HAE Type I or II?
- Am I 12 years old or older?
- Am I currently taking lanadelumab or due to start it within the next 4 weeks?
- Do my medical records have at least 12 months of information about my HAE before I started (or start) lanadelumab?
- Have I never taken lanadelumab in another research study before?
Cosa comporta la partecipazione?
If you take part in this study, the researchers will collect information about your health and your HAE attacks. This information will come from several sources, including your hospital medical records, questionnaires you fill out, and a diary where you can record your HAE attacks. Your study doctors will also provide information.
You won't have any extra visits to the hospital specifically for this study. Instead, the researchers will contact you every three months by phone to follow up and collect information. The study will look at your health for up to 24 months (two years) after you start taking lanadelumab alongside your usual visits with your HAE care team.
Rischi e benefici potenziali
Luoghi (1)
- Barts Health NHS TrustCodice postale verificatoLondra, Regno Unito
Domande comuni
What is Hereditary Angioedema (HAE)?
HAE is a rare condition that causes unexpected and painful swelling attacks in the body.
What is lanadelumab?
Lanadelumab is a medicine used to help prevent or reduce swelling attacks in people with HAE.
Will I have to take a new medicine if I join?
No, this study is for people already using or about to start lanadelumab as part of their regular care, not for trying new medicines.
How often will I be contacted for the study?
The study team will contact you every three months by phone to gather information.
Will joining this study change my regular HAE treatment?
No, joining this study will not change how your HAE is treated by your doctors.
Come saperne di più
Parla sempre con il tuo medico di base o specialista prima di decidere di partecipare a uno studio.
Discussione
Discussione della comunità
Supportato dal nostro forum su community.patient.info. Si prega di essere rispettosi — questo non è un consiglio medico.